



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 6 Jun 2022 (#22)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notices of Special Interest

[NOT-DA-22-058](#) High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior. The mission of the Division of Neuroscience and Behavior (DNB) is to facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of substance use and substance use disorders (SUD) across the lifespan and to guide treatment strategies. The Integrative Neuroscience (IN) Branch within DNB supports research on the cellular mechanisms and circuitry that underlie substance use and SUD. Research supported by the Branch covers: 1) the regulation and plasticity of neurotransmitter and neuromodulatory systems induced by chronic or intermittent exposure to, and/or withdrawal from, addictive substances, 2) the study of substance-induced neurotoxicity, 3) neuron-glia interactions and their modification by substance use and SUD 4) neuroendocrine modulation of neural systems in relation to substance use and SUD, and 5) neuroimmune modulation of the brain including the influences of neuroAIDS and substance-induced neuroinflammation. This notice applies to due dates on or after 5 October 2022 and subsequent receipt dates through 8 January 2026.

[NOT-ES-22-006](#) Climate Change and Health. The National Institute of Environmental Health Science (NIEHS), in partnership with Fogarty International Center (FIC), National Institute of Minority Health and Health Disparities (NIMHD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Heart Blood and Lung Institute (NHBLI) and National Institute of Allergy and Infectious Disease (NIAID) is leading an NIH-wide [Climate Change and Health Initiative \(CCHI\)](#) with the goals of:

- reducing the health threats posed by climate change across the lifespan;
- improving the health of people who are at increased risk from or disparately affected by climate change impacts
- building health resilience among individuals, communities, nations around the world, thus increasing health equity

- As a part of this CCHI, this NOSI encourages applications that address the impact of climate change on health and well-being over the life course, including the health implications of climate change in the United States and globally.

Stellenbosch University will be eligible to apply for the following opportunities: Applicants must select the *IC and associated FOA* to use for submission of an application in response to this NOSI. This notice applies to due dates on or after 8 July 2022 and subsequent receipt dates through 8 May 2025. **The due date is dependent on the mechanism and specific cycle. The selection must align with the IC requirements listed in the NOSI.**

- [PA-20-183](#) – Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-185](#) - Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) - Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-194](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-195](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-196](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
- [PA-20-200](#) - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PAR-21-120](#) - Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
- [PAR-21-251](#) - Emerging Global Leader Award (K43 Independent Clinical Trial Required)
- [PAR-21-252](#) - Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
- [PAR-21-303](#) - Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional)
- [PAR-21-344](#) - Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 Clinical Trials Optional)
- [PAR-22-097](#) - Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)
- [PAR-22-098](#) - Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trials Optional)
- [PAR-22-104](#) - Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)
- [RFA-HG-20-037](#) - Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
- [RFA-HG-20-036](#) - Advancing Genomic Medicine Research (R01 Clinical Trial Optional)

Funding Opportunity Announcements (FOA)

1. National Heart, Lung, and Blood Institute (NHLBI) TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-194](#)

Type: X01

Application Due Date: October 18, 2022, October 17, 2023; October 17, 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications to use [NHLBI-funded TransOmics for Precision Medicine \(TOPMed\)](#) program to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of Heart, Lung, Blood, and Sleep (HLBS) disorders. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as the database for Genotypes and Phenotypes (dbGaP) and NHLBI's BioData Catalyst (BDC). The overall goal is to transition the program from genetic Map to Mechanism (M2) and to fill knowledge gaps that have not been sufficiently covered by existing TOPMed datasets, enabling functional genomics research that will accelerate mechanistic personalized medicine

Budget: NHLBI intends to approve up to 10 projects. Funds are not awarded via this X01 resource access award. The maximum project period is 3 years.

2. Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-23-015](#)

Type: R01

Application Due Date: November 14, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) will support projects proposing mechanistic studies that will transform our understanding of polysubstance use in addiction. These hypothesis-based, exploratory projects may investigate mechanisms of polysubstance use at the behavioral, cognitive, cellular, circuit, genetic, epigenetic, pharmacological and/or computational levels.

Budget: National Institute on Drug Abuse (NIDA) intends to commit \$ 3M in FY 2023 to fund 3-5 awards. Application budgets will be limited to \$350,000 in direct costs/year. The proposed budget needs to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: [Christa](#)
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krottoa Building, Ryneveld Street
Enquiries: [Lizél](#)
e: lizelk@sun.ac.za | t: +27 21 808 2105